BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Science in Vancouver - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://scienceinvancouver.com
X-WR-CALDESC:Events for Science in Vancouver
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Vancouver
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20200308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20201101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20210314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20211107T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20220313T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20221106T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211115T120000
DTEND;TZID=America/Vancouver:20211115T130000
DTSTAMP:20260408T104020
CREATED:20211111T005717Z
LAST-MODIFIED:20211111T005717Z
UID:19289-1636977600-1636981200@scienceinvancouver.com
SUMMARY:Investment Banking for Life Sciences - Job Simulation
DESCRIPTION:*Please Note* This is a two-part event series. Only register if you are able to attend both parts of the job simulation. \nEvent Summary \nHave you ever wondered how biotech startups get their funding or how they identify monetization strategies for their products? Have you heard of investment banks but unsure how they decide which project to fund? This workshop will focus on the role of investment banks and venture capital groups in getting scientific research funded and out in the public. \nDr. Evelyn Pau will shed light on internal processes in investment banking\, walk you through key steps in project evaluations\, and give you a taste of what you might have to do as an analyst in an investment banking industry for life sciences. Attendees will learn skills and resources to perform an opportunity assessment by conducting scientific\, medical\, and clinical due diligence\, market overview and sizing\, competitive landscape\, and other topics to better understand the business case. Attendees will conduct an assignment on Day 1 and share findings on Day 2. \nEvent Takeaways \nGain first-hand experience to conduct opportunity assessment for a new drug target\, indication\, product/technology\, or company.\nUtilize publicly available information to source data\, generate insight on value proposition\, and identify market potential and fit.\nUnderstand the role of a healthcare consultant and see examples of client projects. \n*PLEASE NOTE* This event will be held in TWO parts: \nPart 1: November 15\, 2021- 12pm-1pm PST\nPart 2: November 17\, 2021- 10am-11am PST \nThe Science to Business Network (www.s2bn.org) was founded 10 years ago to break down silos between universities\, industry\, government and the non-profit sector and to foster a culture of collaboration\, partnership and mutual understanding. Importantly\, the S2BN has been focused on building a network of innovative and creative individuals within and around STEM disciplines. Through panel discussions\, workshops\, mentoring programs\, a podcast and other collaborative initiatives\, the S2BN now has 9 chapters across Canada led by more than 70 grassroots volunteers whose activities now reach more than 2500 people a year. \nEvent Speaker \nEvelyn Pau\, PhD\nVice President\, Investment Banking and Recruiting Lead\nBloom Burton \nEvelyn Pau\, Vice President\, Investment Banking and Recruiting Lead joined Bloom Burton & Co. as an Analyst in November 2012. At Bloom Burton\, her responsibilities include monetization planning\, strategy consulting\, and scientific\, clinical and medical due diligence for pharmaceutical\, biotechnology\, and healthcare companies. Evelyn also heads Bloom Burton’s recruiting and talent management efforts as the Recruiting Lead. \nPrior to joining Bloom Burton\, Evelyn was a business development analyst at Tornado Medical Systems (now Tornado Spectral Systems) and a research fellow at SECOR Consulting (now KPMG). Evelyn completed her PhD in Immunology at the University of Toronto\, specializing in genetics and autoimmunity\, and her Bachelor of Medical Sciences Honours in Microbiology and Immunology at Western University. \nCurrently\, Evelyn serves on the Board of Directors of the McMaster Innovation Park.
URL:https://scienceinvancouver.com/event/investment-banking-for-life-sciences-job-simulation/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/11/S2BN_JobSimulation.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211115T120000
DTEND;TZID=America/Vancouver:20211115T130000
DTSTAMP:20260408T104020
CREATED:20211111T005717Z
LAST-MODIFIED:20211111T005717Z
UID:26465-1636977600-1636981200@scienceinvancouver.com
SUMMARY:Investment Banking for Life Sciences - Job Simulation
DESCRIPTION:*Please Note* This is a two-part event series. Only register if you are able to attend both parts of the job simulation. \nEvent Summary \nHave you ever wondered how biotech startups get their funding or how they identify monetization strategies for their products? Have you heard of investment banks but unsure how they decide which project to fund? This workshop will focus on the role of investment banks and venture capital groups in getting scientific research funded and out in the public. \nDr. Evelyn Pau will shed light on internal processes in investment banking\, walk you through key steps in project evaluations\, and give you a taste of what you might have to do as an analyst in an investment banking industry for life sciences. Attendees will learn skills and resources to perform an opportunity assessment by conducting scientific\, medical\, and clinical due diligence\, market overview and sizing\, competitive landscape\, and other topics to better understand the business case. Attendees will conduct an assignment on Day 1 and share findings on Day 2. \nEvent Takeaways \nGain first-hand experience to conduct opportunity assessment for a new drug target\, indication\, product/technology\, or company.\nUtilize publicly available information to source data\, generate insight on value proposition\, and identify market potential and fit.\nUnderstand the role of a healthcare consultant and see examples of client projects. \n*PLEASE NOTE* This event will be held in TWO parts: \nPart 1: November 15\, 2021- 12pm-1pm PST\nPart 2: November 17\, 2021- 10am-11am PST \nThe Science to Business Network (www.s2bn.org) was founded 10 years ago to break down silos between universities\, industry\, government and the non-profit sector and to foster a culture of collaboration\, partnership and mutual understanding. Importantly\, the S2BN has been focused on building a network of innovative and creative individuals within and around STEM disciplines. Through panel discussions\, workshops\, mentoring programs\, a podcast and other collaborative initiatives\, the S2BN now has 9 chapters across Canada led by more than 70 grassroots volunteers whose activities now reach more than 2500 people a year. \nEvent Speaker \nEvelyn Pau\, PhD\nVice President\, Investment Banking and Recruiting Lead\nBloom Burton \nEvelyn Pau\, Vice President\, Investment Banking and Recruiting Lead joined Bloom Burton & Co. as an Analyst in November 2012. At Bloom Burton\, her responsibilities include monetization planning\, strategy consulting\, and scientific\, clinical and medical due diligence for pharmaceutical\, biotechnology\, and healthcare companies. Evelyn also heads Bloom Burton’s recruiting and talent management efforts as the Recruiting Lead. \nPrior to joining Bloom Burton\, Evelyn was a business development analyst at Tornado Medical Systems (now Tornado Spectral Systems) and a research fellow at SECOR Consulting (now KPMG). Evelyn completed her PhD in Immunology at the University of Toronto\, specializing in genetics and autoimmunity\, and her Bachelor of Medical Sciences Honours in Microbiology and Immunology at Western University. \nCurrently\, Evelyn serves on the Board of Directors of the McMaster Innovation Park.
URL:https://scienceinvancouver.com/event/investment-banking-for-life-sciences-job-simulation-2/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/11/S2BN_JobSimulation.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211115T120000
DTEND;TZID=America/Vancouver:20211115T130000
DTSTAMP:20260408T104020
CREATED:20211111T005717Z
LAST-MODIFIED:20211111T005717Z
UID:28079-1636977600-1636981200@scienceinvancouver.com
SUMMARY:Investment Banking for Life Sciences - Job Simulation
DESCRIPTION:*Please Note* This is a two-part event series. Only register if you are able to attend both parts of the job simulation. \nEvent Summary \nHave you ever wondered how biotech startups get their funding or how they identify monetization strategies for their products? Have you heard of investment banks but unsure how they decide which project to fund? This workshop will focus on the role of investment banks and venture capital groups in getting scientific research funded and out in the public. \nDr. Evelyn Pau will shed light on internal processes in investment banking\, walk you through key steps in project evaluations\, and give you a taste of what you might have to do as an analyst in an investment banking industry for life sciences. Attendees will learn skills and resources to perform an opportunity assessment by conducting scientific\, medical\, and clinical due diligence\, market overview and sizing\, competitive landscape\, and other topics to better understand the business case. Attendees will conduct an assignment on Day 1 and share findings on Day 2. \nEvent Takeaways \nGain first-hand experience to conduct opportunity assessment for a new drug target\, indication\, product/technology\, or company.\nUtilize publicly available information to source data\, generate insight on value proposition\, and identify market potential and fit.\nUnderstand the role of a healthcare consultant and see examples of client projects. \n*PLEASE NOTE* This event will be held in TWO parts: \nPart 1: November 15\, 2021- 12pm-1pm PST\nPart 2: November 17\, 2021- 10am-11am PST \nThe Science to Business Network (www.s2bn.org) was founded 10 years ago to break down silos between universities\, industry\, government and the non-profit sector and to foster a culture of collaboration\, partnership and mutual understanding. Importantly\, the S2BN has been focused on building a network of innovative and creative individuals within and around STEM disciplines. Through panel discussions\, workshops\, mentoring programs\, a podcast and other collaborative initiatives\, the S2BN now has 9 chapters across Canada led by more than 70 grassroots volunteers whose activities now reach more than 2500 people a year. \nEvent Speaker \nEvelyn Pau\, PhD\nVice President\, Investment Banking and Recruiting Lead\nBloom Burton \nEvelyn Pau\, Vice President\, Investment Banking and Recruiting Lead joined Bloom Burton & Co. as an Analyst in November 2012. At Bloom Burton\, her responsibilities include monetization planning\, strategy consulting\, and scientific\, clinical and medical due diligence for pharmaceutical\, biotechnology\, and healthcare companies. Evelyn also heads Bloom Burton’s recruiting and talent management efforts as the Recruiting Lead. \nPrior to joining Bloom Burton\, Evelyn was a business development analyst at Tornado Medical Systems (now Tornado Spectral Systems) and a research fellow at SECOR Consulting (now KPMG). Evelyn completed her PhD in Immunology at the University of Toronto\, specializing in genetics and autoimmunity\, and her Bachelor of Medical Sciences Honours in Microbiology and Immunology at Western University. \nCurrently\, Evelyn serves on the Board of Directors of the McMaster Innovation Park.
URL:https://scienceinvancouver.com/event/investment-banking-for-life-sciences-job-simulation-3/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/11/S2BN_JobSimulation.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211115T120000
DTEND;TZID=America/Vancouver:20211115T130000
DTSTAMP:20260408T104020
CREATED:20211111T005717Z
LAST-MODIFIED:20211111T005717Z
UID:31162-1636977600-1636981200@scienceinvancouver.com
SUMMARY:Investment Banking for Life Sciences - Job Simulation
DESCRIPTION:*Please Note* This is a two-part event series. Only register if you are able to attend both parts of the job simulation. \nEvent Summary \nHave you ever wondered how biotech startups get their funding or how they identify monetization strategies for their products? Have you heard of investment banks but unsure how they decide which project to fund? This workshop will focus on the role of investment banks and venture capital groups in getting scientific research funded and out in the public. \nDr. Evelyn Pau will shed light on internal processes in investment banking\, walk you through key steps in project evaluations\, and give you a taste of what you might have to do as an analyst in an investment banking industry for life sciences. Attendees will learn skills and resources to perform an opportunity assessment by conducting scientific\, medical\, and clinical due diligence\, market overview and sizing\, competitive landscape\, and other topics to better understand the business case. Attendees will conduct an assignment on Day 1 and share findings on Day 2. \nEvent Takeaways \nGain first-hand experience to conduct opportunity assessment for a new drug target\, indication\, product/technology\, or company.\nUtilize publicly available information to source data\, generate insight on value proposition\, and identify market potential and fit.\nUnderstand the role of a healthcare consultant and see examples of client projects. \n*PLEASE NOTE* This event will be held in TWO parts: \nPart 1: November 15\, 2021- 12pm-1pm PST\nPart 2: November 17\, 2021- 10am-11am PST \nThe Science to Business Network (www.s2bn.org) was founded 10 years ago to break down silos between universities\, industry\, government and the non-profit sector and to foster a culture of collaboration\, partnership and mutual understanding. Importantly\, the S2BN has been focused on building a network of innovative and creative individuals within and around STEM disciplines. Through panel discussions\, workshops\, mentoring programs\, a podcast and other collaborative initiatives\, the S2BN now has 9 chapters across Canada led by more than 70 grassroots volunteers whose activities now reach more than 2500 people a year. \nEvent Speaker \nEvelyn Pau\, PhD\nVice President\, Investment Banking and Recruiting Lead\nBloom Burton \nEvelyn Pau\, Vice President\, Investment Banking and Recruiting Lead joined Bloom Burton & Co. as an Analyst in November 2012. At Bloom Burton\, her responsibilities include monetization planning\, strategy consulting\, and scientific\, clinical and medical due diligence for pharmaceutical\, biotechnology\, and healthcare companies. Evelyn also heads Bloom Burton’s recruiting and talent management efforts as the Recruiting Lead. \nPrior to joining Bloom Burton\, Evelyn was a business development analyst at Tornado Medical Systems (now Tornado Spectral Systems) and a research fellow at SECOR Consulting (now KPMG). Evelyn completed her PhD in Immunology at the University of Toronto\, specializing in genetics and autoimmunity\, and her Bachelor of Medical Sciences Honours in Microbiology and Immunology at Western University. \nCurrently\, Evelyn serves on the Board of Directors of the McMaster Innovation Park.
URL:https://scienceinvancouver.com/event/investment-banking-for-life-sciences-job-simulation-4/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/11/S2BN_JobSimulation.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211115T120000
DTEND;TZID=America/Vancouver:20211115T130000
DTSTAMP:20260408T104020
CREATED:20211111T005717Z
LAST-MODIFIED:20211111T005717Z
UID:32622-1636977600-1636981200@scienceinvancouver.com
SUMMARY:Investment Banking for Life Sciences - Job Simulation
DESCRIPTION:*Please Note* This is a two-part event series. Only register if you are able to attend both parts of the job simulation. \nEvent Summary \nHave you ever wondered how biotech startups get their funding or how they identify monetization strategies for their products? Have you heard of investment banks but unsure how they decide which project to fund? This workshop will focus on the role of investment banks and venture capital groups in getting scientific research funded and out in the public. \nDr. Evelyn Pau will shed light on internal processes in investment banking\, walk you through key steps in project evaluations\, and give you a taste of what you might have to do as an analyst in an investment banking industry for life sciences. Attendees will learn skills and resources to perform an opportunity assessment by conducting scientific\, medical\, and clinical due diligence\, market overview and sizing\, competitive landscape\, and other topics to better understand the business case. Attendees will conduct an assignment on Day 1 and share findings on Day 2. \nEvent Takeaways \nGain first-hand experience to conduct opportunity assessment for a new drug target\, indication\, product/technology\, or company.\nUtilize publicly available information to source data\, generate insight on value proposition\, and identify market potential and fit.\nUnderstand the role of a healthcare consultant and see examples of client projects. \n*PLEASE NOTE* This event will be held in TWO parts: \nPart 1: November 15\, 2021- 12pm-1pm PST\nPart 2: November 17\, 2021- 10am-11am PST \nThe Science to Business Network (www.s2bn.org) was founded 10 years ago to break down silos between universities\, industry\, government and the non-profit sector and to foster a culture of collaboration\, partnership and mutual understanding. Importantly\, the S2BN has been focused on building a network of innovative and creative individuals within and around STEM disciplines. Through panel discussions\, workshops\, mentoring programs\, a podcast and other collaborative initiatives\, the S2BN now has 9 chapters across Canada led by more than 70 grassroots volunteers whose activities now reach more than 2500 people a year. \nEvent Speaker \nEvelyn Pau\, PhD\nVice President\, Investment Banking and Recruiting Lead\nBloom Burton \nEvelyn Pau\, Vice President\, Investment Banking and Recruiting Lead joined Bloom Burton & Co. as an Analyst in November 2012. At Bloom Burton\, her responsibilities include monetization planning\, strategy consulting\, and scientific\, clinical and medical due diligence for pharmaceutical\, biotechnology\, and healthcare companies. Evelyn also heads Bloom Burton’s recruiting and talent management efforts as the Recruiting Lead. \nPrior to joining Bloom Burton\, Evelyn was a business development analyst at Tornado Medical Systems (now Tornado Spectral Systems) and a research fellow at SECOR Consulting (now KPMG). Evelyn completed her PhD in Immunology at the University of Toronto\, specializing in genetics and autoimmunity\, and her Bachelor of Medical Sciences Honours in Microbiology and Immunology at Western University. \nCurrently\, Evelyn serves on the Board of Directors of the McMaster Innovation Park.
URL:https://scienceinvancouver.com/event/investment-banking-for-life-sciences-job-simulation-5/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/11/S2BN_JobSimulation.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211117T093000
DTEND;TZID=America/Vancouver:20211118T123000
DTSTAMP:20260408T104020
CREATED:20210716T222728Z
LAST-MODIFIED:20210716T222728Z
UID:17443-1637141400-1637238600@scienceinvancouver.com
SUMMARY:Image Guided Therapeutics and Diagnostics Symposium
DESCRIPTION:Event Details\nThis event is running from 17 November 2021 until 18 November 2021. It is next occurring on 17 November 2021 9:30 am. \n\nCategories: Conference | Symposium\nUpcoming Dates:\n\n17 November 2021 9:30 am\n18 November 2021 9:30 am\n\n\n\n\n\n\nSave the Date!\nBuilding off the success of the IGT webinar series\, Image Guided Therapeutics and Diagnostics is a 2-day symposium that will bring together clinicians\, researchers\, students\, and industry organizations who are interested in emerging diagnostic and therapeutic health technologies. \nThe symposium will not only provide an opportunity to network and identify opportunities for collaboration and partnership but also serve as a showcase for new innovations and products for industry partners. Register for a formula of networking\, matchmaking\, and groundbreaking content in an immersive and educational environment. \nFeatured: \n\nKeynote addresses from Dr. Maria Drangova\, Western University; Dr. Terry Peters\, Robarts Research Institute; Dr. Robin Shandas\, University of Colorado; and Dr. Purang Abolmaesumi\, UBC\nInvited talks on themes such as diagnostic imaging\, artificial intelligence\, and image guided therapies for a multitude of applications\nA Panel Discussion with our keynote speakers\nNetworking with Canada’s IGTD community\n\nCall for Abstracts! \nThe IGTD Committee is pleased to invite researchers\, scientists\, clinicians and students to participate actively in this symposium\, which will provide an interactive platform to exchange thoughts and experiences. Authors can submit their abstracts for invited oral and poster presentations\, to be delivered virtually through Zoom and Gather.Town. The organizers welcome the submissions of original contributions to the field of image-guided therapeutics and diagnostics. \nThe deadline for abstract submission is July 17th\, 2021.
URL:https://scienceinvancouver.com/event/image-guided-therapeutics-and-diagnostics-symposium/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211117T093000
DTEND;TZID=America/Vancouver:20211118T123000
DTSTAMP:20260408T104020
CREATED:20210716T222728Z
LAST-MODIFIED:20210716T222728Z
UID:26417-1637141400-1637238600@scienceinvancouver.com
SUMMARY:Image Guided Therapeutics and Diagnostics Symposium
DESCRIPTION:Event Details\nThis event is running from 17 November 2021 until 18 November 2021. It is next occurring on 17 November 2021 9:30 am. \n\nCategories: Conference | Symposium\nUpcoming Dates:\n\n17 November 2021 9:30 am\n18 November 2021 9:30 am\n\n\n\n\n\n\nSave the Date!\nBuilding off the success of the IGT webinar series\, Image Guided Therapeutics and Diagnostics is a 2-day symposium that will bring together clinicians\, researchers\, students\, and industry organizations who are interested in emerging diagnostic and therapeutic health technologies. \nThe symposium will not only provide an opportunity to network and identify opportunities for collaboration and partnership but also serve as a showcase for new innovations and products for industry partners. Register for a formula of networking\, matchmaking\, and groundbreaking content in an immersive and educational environment. \nFeatured: \n\nKeynote addresses from Dr. Maria Drangova\, Western University; Dr. Terry Peters\, Robarts Research Institute; Dr. Robin Shandas\, University of Colorado; and Dr. Purang Abolmaesumi\, UBC\nInvited talks on themes such as diagnostic imaging\, artificial intelligence\, and image guided therapies for a multitude of applications\nA Panel Discussion with our keynote speakers\nNetworking with Canada’s IGTD community\n\nCall for Abstracts! \nThe IGTD Committee is pleased to invite researchers\, scientists\, clinicians and students to participate actively in this symposium\, which will provide an interactive platform to exchange thoughts and experiences. Authors can submit their abstracts for invited oral and poster presentations\, to be delivered virtually through Zoom and Gather.Town. The organizers welcome the submissions of original contributions to the field of image-guided therapeutics and diagnostics. \nThe deadline for abstract submission is July 17th\, 2021.
URL:https://scienceinvancouver.com/event/image-guided-therapeutics-and-diagnostics-symposium-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211117T093000
DTEND;TZID=America/Vancouver:20211118T123000
DTSTAMP:20260408T104020
CREATED:20210716T222728Z
LAST-MODIFIED:20210716T222728Z
UID:28032-1637141400-1637238600@scienceinvancouver.com
SUMMARY:Image Guided Therapeutics and Diagnostics Symposium
DESCRIPTION:Event Details\nThis event is running from 17 November 2021 until 18 November 2021. It is next occurring on 17 November 2021 9:30 am. \n\nCategories: Conference | Symposium\nUpcoming Dates:\n\n17 November 2021 9:30 am\n18 November 2021 9:30 am\n\n\n\n\n\n\nSave the Date!\nBuilding off the success of the IGT webinar series\, Image Guided Therapeutics and Diagnostics is a 2-day symposium that will bring together clinicians\, researchers\, students\, and industry organizations who are interested in emerging diagnostic and therapeutic health technologies. \nThe symposium will not only provide an opportunity to network and identify opportunities for collaboration and partnership but also serve as a showcase for new innovations and products for industry partners. Register for a formula of networking\, matchmaking\, and groundbreaking content in an immersive and educational environment. \nFeatured: \n\nKeynote addresses from Dr. Maria Drangova\, Western University; Dr. Terry Peters\, Robarts Research Institute; Dr. Robin Shandas\, University of Colorado; and Dr. Purang Abolmaesumi\, UBC\nInvited talks on themes such as diagnostic imaging\, artificial intelligence\, and image guided therapies for a multitude of applications\nA Panel Discussion with our keynote speakers\nNetworking with Canada’s IGTD community\n\nCall for Abstracts! \nThe IGTD Committee is pleased to invite researchers\, scientists\, clinicians and students to participate actively in this symposium\, which will provide an interactive platform to exchange thoughts and experiences. Authors can submit their abstracts for invited oral and poster presentations\, to be delivered virtually through Zoom and Gather.Town. The organizers welcome the submissions of original contributions to the field of image-guided therapeutics and diagnostics. \nThe deadline for abstract submission is July 17th\, 2021.
URL:https://scienceinvancouver.com/event/image-guided-therapeutics-and-diagnostics-symposium-3/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211117T093000
DTEND;TZID=America/Vancouver:20211118T123000
DTSTAMP:20260408T104020
CREATED:20210716T222728Z
LAST-MODIFIED:20210716T222728Z
UID:31115-1637141400-1637238600@scienceinvancouver.com
SUMMARY:Image Guided Therapeutics and Diagnostics Symposium
DESCRIPTION:Event Details\nThis event is running from 17 November 2021 until 18 November 2021. It is next occurring on 17 November 2021 9:30 am. \n\nCategories: Conference | Symposium\nUpcoming Dates:\n\n17 November 2021 9:30 am\n18 November 2021 9:30 am\n\n\n\n\n\n\nSave the Date!\nBuilding off the success of the IGT webinar series\, Image Guided Therapeutics and Diagnostics is a 2-day symposium that will bring together clinicians\, researchers\, students\, and industry organizations who are interested in emerging diagnostic and therapeutic health technologies. \nThe symposium will not only provide an opportunity to network and identify opportunities for collaboration and partnership but also serve as a showcase for new innovations and products for industry partners. Register for a formula of networking\, matchmaking\, and groundbreaking content in an immersive and educational environment. \nFeatured: \n\nKeynote addresses from Dr. Maria Drangova\, Western University; Dr. Terry Peters\, Robarts Research Institute; Dr. Robin Shandas\, University of Colorado; and Dr. Purang Abolmaesumi\, UBC\nInvited talks on themes such as diagnostic imaging\, artificial intelligence\, and image guided therapies for a multitude of applications\nA Panel Discussion with our keynote speakers\nNetworking with Canada’s IGTD community\n\nCall for Abstracts! \nThe IGTD Committee is pleased to invite researchers\, scientists\, clinicians and students to participate actively in this symposium\, which will provide an interactive platform to exchange thoughts and experiences. Authors can submit their abstracts for invited oral and poster presentations\, to be delivered virtually through Zoom and Gather.Town. The organizers welcome the submissions of original contributions to the field of image-guided therapeutics and diagnostics. \nThe deadline for abstract submission is July 17th\, 2021.
URL:https://scienceinvancouver.com/event/image-guided-therapeutics-and-diagnostics-symposium-4/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211117T093000
DTEND;TZID=America/Vancouver:20211118T123000
DTSTAMP:20260408T104020
CREATED:20210716T222728Z
LAST-MODIFIED:20210716T222728Z
UID:32575-1637141400-1637238600@scienceinvancouver.com
SUMMARY:Image Guided Therapeutics and Diagnostics Symposium
DESCRIPTION:Event Details\nThis event is running from 17 November 2021 until 18 November 2021. It is next occurring on 17 November 2021 9:30 am. \n\nCategories: Conference | Symposium\nUpcoming Dates:\n\n17 November 2021 9:30 am\n18 November 2021 9:30 am\n\n\n\n\n\n\nSave the Date!\nBuilding off the success of the IGT webinar series\, Image Guided Therapeutics and Diagnostics is a 2-day symposium that will bring together clinicians\, researchers\, students\, and industry organizations who are interested in emerging diagnostic and therapeutic health technologies. \nThe symposium will not only provide an opportunity to network and identify opportunities for collaboration and partnership but also serve as a showcase for new innovations and products for industry partners. Register for a formula of networking\, matchmaking\, and groundbreaking content in an immersive and educational environment. \nFeatured: \n\nKeynote addresses from Dr. Maria Drangova\, Western University; Dr. Terry Peters\, Robarts Research Institute; Dr. Robin Shandas\, University of Colorado; and Dr. Purang Abolmaesumi\, UBC\nInvited talks on themes such as diagnostic imaging\, artificial intelligence\, and image guided therapies for a multitude of applications\nA Panel Discussion with our keynote speakers\nNetworking with Canada’s IGTD community\n\nCall for Abstracts! \nThe IGTD Committee is pleased to invite researchers\, scientists\, clinicians and students to participate actively in this symposium\, which will provide an interactive platform to exchange thoughts and experiences. Authors can submit their abstracts for invited oral and poster presentations\, to be delivered virtually through Zoom and Gather.Town. The organizers welcome the submissions of original contributions to the field of image-guided therapeutics and diagnostics. \nThe deadline for abstract submission is July 17th\, 2021.
URL:https://scienceinvancouver.com/event/image-guided-therapeutics-and-diagnostics-symposium-5/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211117T150000
DTEND;TZID=America/Vancouver:20211117T163000
DTSTAMP:20260408T104020
CREATED:20211115T000850Z
LAST-MODIFIED:20211115T000850Z
UID:19347-1637161200-1637166600@scienceinvancouver.com
SUMMARY:MSL Seminar Series: November Trainee Talks
DESCRIPTION:Date: Wednesday November 17th\, 3:00-4:30pm \nHost: Dr. Paul Pavlidis \nThis seminar will be presented in a hybrid format. All speakers will be delivering talks in person at the MSL Lecture Theatre (room 102). Audience members are welcome to attend either in person or via the zoom link. Those connecting via zoom will be able to ask questions during the Q&A portion using the chat function. \nZoom registration link:\nhttps://ubc.zoom.us/meeting/register/u5Ivf-ysqDIjGteaN13pGa3f5LetWjNG4Ndk \nSeminar Schedule:\nTrainee Talk 1:  Adele Khavari – Kastrup Lab\nRole of coagulation factor XII in decompression sickness\n \nTrainee Talk 2: Christopher Lee – Kronstad Lab\nInvestigating the role of 3-hydroxyanthranillic acid on iron uptake and virulence in the fungal pathogen ‘Cryptococcus neoformans’ \nTrainee Talk 3: Anne-Sophie Sack – Snutch Lab\nThe Role of Cav3.2 T-type Calcium Channels in Dentate Gyrus Excitability \nFaculty Talk: Dr. Wilf Jefferies\nCurrent Research Vignettes
URL:https://scienceinvancouver.com/event/msl-seminar-series-november-trainee-talks/
LOCATION:Michael Smith Laboratories & Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/11/MSL-Trainee-Talks-Nov-17th-2021-1536x864-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211117T150000
DTEND;TZID=America/Vancouver:20211117T163000
DTSTAMP:20260408T104020
CREATED:20211115T000850Z
LAST-MODIFIED:20211115T000850Z
UID:26468-1637161200-1637166600@scienceinvancouver.com
SUMMARY:MSL Seminar Series: November Trainee Talks
DESCRIPTION:Date: Wednesday November 17th\, 3:00-4:30pm \nHost: Dr. Paul Pavlidis \nThis seminar will be presented in a hybrid format. All speakers will be delivering talks in person at the MSL Lecture Theatre (room 102). Audience members are welcome to attend either in person or via the zoom link. Those connecting via zoom will be able to ask questions during the Q&A portion using the chat function. \nZoom registration link:\nhttps://ubc.zoom.us/meeting/register/u5Ivf-ysqDIjGteaN13pGa3f5LetWjNG4Ndk \nSeminar Schedule:\nTrainee Talk 1:  Adele Khavari – Kastrup Lab\nRole of coagulation factor XII in decompression sickness\n \nTrainee Talk 2: Christopher Lee – Kronstad Lab\nInvestigating the role of 3-hydroxyanthranillic acid on iron uptake and virulence in the fungal pathogen ‘Cryptococcus neoformans’ \nTrainee Talk 3: Anne-Sophie Sack – Snutch Lab\nThe Role of Cav3.2 T-type Calcium Channels in Dentate Gyrus Excitability \nFaculty Talk: Dr. Wilf Jefferies\nCurrent Research Vignettes
URL:https://scienceinvancouver.com/event/msl-seminar-series-november-trainee-talks-2/
LOCATION:Michael Smith Laboratories & Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/11/MSL-Trainee-Talks-Nov-17th-2021-1536x864-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211117T150000
DTEND;TZID=America/Vancouver:20211117T163000
DTSTAMP:20260408T104020
CREATED:20211115T000850Z
LAST-MODIFIED:20211115T000850Z
UID:28083-1637161200-1637166600@scienceinvancouver.com
SUMMARY:MSL Seminar Series: November Trainee Talks
DESCRIPTION:Date: Wednesday November 17th\, 3:00-4:30pm \nHost: Dr. Paul Pavlidis \nThis seminar will be presented in a hybrid format. All speakers will be delivering talks in person at the MSL Lecture Theatre (room 102). Audience members are welcome to attend either in person or via the zoom link. Those connecting via zoom will be able to ask questions during the Q&A portion using the chat function. \nZoom registration link:\nhttps://ubc.zoom.us/meeting/register/u5Ivf-ysqDIjGteaN13pGa3f5LetWjNG4Ndk \nSeminar Schedule:\nTrainee Talk 1:  Adele Khavari – Kastrup Lab\nRole of coagulation factor XII in decompression sickness\n \nTrainee Talk 2: Christopher Lee – Kronstad Lab\nInvestigating the role of 3-hydroxyanthranillic acid on iron uptake and virulence in the fungal pathogen ‘Cryptococcus neoformans’ \nTrainee Talk 3: Anne-Sophie Sack – Snutch Lab\nThe Role of Cav3.2 T-type Calcium Channels in Dentate Gyrus Excitability \nFaculty Talk: Dr. Wilf Jefferies\nCurrent Research Vignettes
URL:https://scienceinvancouver.com/event/msl-seminar-series-november-trainee-talks-3/
LOCATION:Michael Smith Laboratories & Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/11/MSL-Trainee-Talks-Nov-17th-2021-1536x864-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211117T150000
DTEND;TZID=America/Vancouver:20211117T163000
DTSTAMP:20260408T104020
CREATED:20211115T000850Z
LAST-MODIFIED:20211115T000850Z
UID:31166-1637161200-1637166600@scienceinvancouver.com
SUMMARY:MSL Seminar Series: November Trainee Talks
DESCRIPTION:Date: Wednesday November 17th\, 3:00-4:30pm \nHost: Dr. Paul Pavlidis \nThis seminar will be presented in a hybrid format. All speakers will be delivering talks in person at the MSL Lecture Theatre (room 102). Audience members are welcome to attend either in person or via the zoom link. Those connecting via zoom will be able to ask questions during the Q&A portion using the chat function. \nZoom registration link:\nhttps://ubc.zoom.us/meeting/register/u5Ivf-ysqDIjGteaN13pGa3f5LetWjNG4Ndk \nSeminar Schedule:\nTrainee Talk 1:  Adele Khavari – Kastrup Lab\nRole of coagulation factor XII in decompression sickness\n \nTrainee Talk 2: Christopher Lee – Kronstad Lab\nInvestigating the role of 3-hydroxyanthranillic acid on iron uptake and virulence in the fungal pathogen ‘Cryptococcus neoformans’ \nTrainee Talk 3: Anne-Sophie Sack – Snutch Lab\nThe Role of Cav3.2 T-type Calcium Channels in Dentate Gyrus Excitability \nFaculty Talk: Dr. Wilf Jefferies\nCurrent Research Vignettes
URL:https://scienceinvancouver.com/event/msl-seminar-series-november-trainee-talks-4/
LOCATION:Michael Smith Laboratories & Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/11/MSL-Trainee-Talks-Nov-17th-2021-1536x864-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211117T150000
DTEND;TZID=America/Vancouver:20211117T163000
DTSTAMP:20260408T104020
CREATED:20211115T000850Z
LAST-MODIFIED:20211115T000850Z
UID:32626-1637161200-1637166600@scienceinvancouver.com
SUMMARY:MSL Seminar Series: November Trainee Talks
DESCRIPTION:Date: Wednesday November 17th\, 3:00-4:30pm \nHost: Dr. Paul Pavlidis \nThis seminar will be presented in a hybrid format. All speakers will be delivering talks in person at the MSL Lecture Theatre (room 102). Audience members are welcome to attend either in person or via the zoom link. Those connecting via zoom will be able to ask questions during the Q&A portion using the chat function. \nZoom registration link:\nhttps://ubc.zoom.us/meeting/register/u5Ivf-ysqDIjGteaN13pGa3f5LetWjNG4Ndk \nSeminar Schedule:\nTrainee Talk 1:  Adele Khavari – Kastrup Lab\nRole of coagulation factor XII in decompression sickness\n \nTrainee Talk 2: Christopher Lee – Kronstad Lab\nInvestigating the role of 3-hydroxyanthranillic acid on iron uptake and virulence in the fungal pathogen ‘Cryptococcus neoformans’ \nTrainee Talk 3: Anne-Sophie Sack – Snutch Lab\nThe Role of Cav3.2 T-type Calcium Channels in Dentate Gyrus Excitability \nFaculty Talk: Dr. Wilf Jefferies\nCurrent Research Vignettes
URL:https://scienceinvancouver.com/event/msl-seminar-series-november-trainee-talks-5/
LOCATION:Michael Smith Laboratories & Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/11/MSL-Trainee-Talks-Nov-17th-2021-1536x864-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211118T080000
DTEND;TZID=America/Vancouver:20211118T103000
DTSTAMP:20260408T104020
CREATED:20211102T202143Z
LAST-MODIFIED:20211102T204349Z
UID:19118-1637222400-1637231400@scienceinvancouver.com
SUMMARY:2021 Don Rix Distinguished Keynote Address
DESCRIPTION:The United Kingdom (UK) has made an unprecedented investment in genomics and worked hard to embed this transformative technology into its healthcare infrastructure.  How has this helped the UK  improve health care delivery?  How did genomics help the UK prepare for and work through the challenges of the pandemic?  And what can Canada learn from this experience? \nAt 8:00am on November 18\, 2021\, Genome BC proudly presents Professor Dame Sue Hill as the speaker for their 12th Annual Don Rix Distinguished Keynote Address.  As the Chief Scientific Officer for England and Senior Responsible Officer for Genomics in NHS England and NHS Improvement\, Sue established the NHS Genomic Medicine Centres and led the NHS contribution to the 100\,000 Genomes Project. \nWe hope you’ll join us as Professor Dame Sue Hill shares her insights and looks to answer these questions.
URL:https://scienceinvancouver.com/event/2021-don-rix-distinguished-keynote-address/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/11/DRDK2021.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211118T080000
DTEND;TZID=America/Vancouver:20211118T103000
DTSTAMP:20260408T104020
CREATED:20211102T202143Z
LAST-MODIFIED:20211102T202143Z
UID:26457-1637222400-1637231400@scienceinvancouver.com
SUMMARY:2021 Don Rix Distinguished Keynote Address
DESCRIPTION:The United Kingdom (UK) has made an unprecedented investment in genomics and worked hard to embed this transformative technology into its healthcare infrastructure.  How has this helped the UK  improve health care delivery?  How did genomics help the UK prepare for and work through the challenges of the pandemic?  And what can Canada learn from this experience? \nAt 8:00am on November 18\, 2021\, Genome BC proudly presents Professor Dame Sue Hill as the speaker for their 12th Annual Don Rix Distinguished Keynote Address.  As the Chief Scientific Officer for England and Senior Responsible Officer for Genomics in NHS England and NHS Improvement\, Sue established the NHS Genomic Medicine Centres and led the NHS contribution to the 100\,000 Genomes Project. \nWe hope you’ll join us as Professor Dame Sue Hill shares her insights and looks to answer these questions.
URL:https://scienceinvancouver.com/event/2021-don-rix-distinguished-keynote-address-2/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/11/DRDK2021.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211118T080000
DTEND;TZID=America/Vancouver:20211118T103000
DTSTAMP:20260408T104020
CREATED:20211102T202143Z
LAST-MODIFIED:20211102T202143Z
UID:28072-1637222400-1637231400@scienceinvancouver.com
SUMMARY:2021 Don Rix Distinguished Keynote Address
DESCRIPTION:The United Kingdom (UK) has made an unprecedented investment in genomics and worked hard to embed this transformative technology into its healthcare infrastructure.  How has this helped the UK  improve health care delivery?  How did genomics help the UK prepare for and work through the challenges of the pandemic?  And what can Canada learn from this experience? \nAt 8:00am on November 18\, 2021\, Genome BC proudly presents Professor Dame Sue Hill as the speaker for their 12th Annual Don Rix Distinguished Keynote Address.  As the Chief Scientific Officer for England and Senior Responsible Officer for Genomics in NHS England and NHS Improvement\, Sue established the NHS Genomic Medicine Centres and led the NHS contribution to the 100\,000 Genomes Project. \nWe hope you’ll join us as Professor Dame Sue Hill shares her insights and looks to answer these questions.
URL:https://scienceinvancouver.com/event/2021-don-rix-distinguished-keynote-address-3/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/11/DRDK2021.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211118T080000
DTEND;TZID=America/Vancouver:20211118T103000
DTSTAMP:20260408T104020
CREATED:20211102T202143Z
LAST-MODIFIED:20211102T202143Z
UID:31155-1637222400-1637231400@scienceinvancouver.com
SUMMARY:2021 Don Rix Distinguished Keynote Address
DESCRIPTION:The United Kingdom (UK) has made an unprecedented investment in genomics and worked hard to embed this transformative technology into its healthcare infrastructure.  How has this helped the UK  improve health care delivery?  How did genomics help the UK prepare for and work through the challenges of the pandemic?  And what can Canada learn from this experience? \nAt 8:00am on November 18\, 2021\, Genome BC proudly presents Professor Dame Sue Hill as the speaker for their 12th Annual Don Rix Distinguished Keynote Address.  As the Chief Scientific Officer for England and Senior Responsible Officer for Genomics in NHS England and NHS Improvement\, Sue established the NHS Genomic Medicine Centres and led the NHS contribution to the 100\,000 Genomes Project. \nWe hope you’ll join us as Professor Dame Sue Hill shares her insights and looks to answer these questions.
URL:https://scienceinvancouver.com/event/2021-don-rix-distinguished-keynote-address-4/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/11/DRDK2021.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211118T080000
DTEND;TZID=America/Vancouver:20211118T103000
DTSTAMP:20260408T104020
CREATED:20211102T202143Z
LAST-MODIFIED:20211102T202143Z
UID:32615-1637222400-1637231400@scienceinvancouver.com
SUMMARY:2021 Don Rix Distinguished Keynote Address
DESCRIPTION:The United Kingdom (UK) has made an unprecedented investment in genomics and worked hard to embed this transformative technology into its healthcare infrastructure.  How has this helped the UK  improve health care delivery?  How did genomics help the UK prepare for and work through the challenges of the pandemic?  And what can Canada learn from this experience? \nAt 8:00am on November 18\, 2021\, Genome BC proudly presents Professor Dame Sue Hill as the speaker for their 12th Annual Don Rix Distinguished Keynote Address.  As the Chief Scientific Officer for England and Senior Responsible Officer for Genomics in NHS England and NHS Improvement\, Sue established the NHS Genomic Medicine Centres and led the NHS contribution to the 100\,000 Genomes Project. \nWe hope you’ll join us as Professor Dame Sue Hill shares her insights and looks to answer these questions.
URL:https://scienceinvancouver.com/event/2021-don-rix-distinguished-keynote-address-5/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/11/DRDK2021.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211118T083000
DTEND;TZID=America/Vancouver:20211120T120000
DTSTAMP:20260408T104020
CREATED:20210920T030135Z
LAST-MODIFIED:20211115T175106Z
UID:18384-1637224200-1637409600@scienceinvancouver.com
SUMMARY:BC Cancer Summit
DESCRIPTION:Registration for the virtual 2021 BC Cancer Summit is now open! \nWe are delighted to host the BC Cancer Summit virtually this year from November 18 to 20. The Summit provides education\, professional development and relationship building opportunities for oncology professionals from all specialties and disciplines. \nThis year’s Summit will feature: \n\nKeynote presentation by the Right Honourable Beverley McLachlin\nKeynote on PRecision oncology Evidence Development in Cancer Treatment (PREDiCT) and Precision Oncology for Young People (PROFYLE)\nA selection of breakouts sessions\, a Terry Fox Research Institute (TFRI) BC Node Research Day\, and poster session\nCelebration of award recipients of the 2021 Terry Fox Medal and BC Cancer Excellence Awards\n\nClick here to register.\n\nWe look forward to having you join us at the Summit. Please register by 5 p.m.\, November 17.
URL:https://scienceinvancouver.com/event/bc-cancer-summit-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211118T083000
DTEND;TZID=America/Vancouver:20211120T120000
DTSTAMP:20260408T104020
CREATED:20210920T030135Z
LAST-MODIFIED:20210920T030135Z
UID:26438-1637224200-1637409600@scienceinvancouver.com
SUMMARY:BC Cancer Summit
DESCRIPTION:Registration for the virtual 2021 BC Cancer Summit is now open! \nWe are delighted to host the BC Cancer Summit virtually this year from November 18 to 20. The Summit provides education\, professional development and relationship building opportunities for oncology professionals from all specialties and disciplines. \nThis year’s Summit will feature: \n\nKeynote presentation by the Right Honourable Beverley McLachlin\nKeynote on PRecision oncology Evidence Development in Cancer Treatment (PREDiCT) and Precision Oncology for Young People (PROFYLE)\nA selection of breakouts sessions\, a Terry Fox Research Institute (TFRI) BC Node Research Day\, and poster session\nCelebration of award recipients of the 2021 Terry Fox Medal and BC Cancer Excellence Awards\n\nClick here to register.\n\nWe look forward to having you join us at the Summit. Please register by 5 p.m.\, November 17.
URL:https://scienceinvancouver.com/event/bc-cancer-summit-2-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211118T083000
DTEND;TZID=America/Vancouver:20211120T120000
DTSTAMP:20260408T104020
CREATED:20210920T030135Z
LAST-MODIFIED:20210920T030135Z
UID:28053-1637224200-1637409600@scienceinvancouver.com
SUMMARY:BC Cancer Summit
DESCRIPTION:Registration for the virtual 2021 BC Cancer Summit is now open! \nWe are delighted to host the BC Cancer Summit virtually this year from November 18 to 20. The Summit provides education\, professional development and relationship building opportunities for oncology professionals from all specialties and disciplines. \nThis year’s Summit will feature: \n\nKeynote presentation by the Right Honourable Beverley McLachlin\nKeynote on PRecision oncology Evidence Development in Cancer Treatment (PREDiCT) and Precision Oncology for Young People (PROFYLE)\nA selection of breakouts sessions\, a Terry Fox Research Institute (TFRI) BC Node Research Day\, and poster session\nCelebration of award recipients of the 2021 Terry Fox Medal and BC Cancer Excellence Awards\n\nClick here to register.\n\nWe look forward to having you join us at the Summit. Please register by 5 p.m.\, November 17.
URL:https://scienceinvancouver.com/event/bc-cancer-summit-2-3/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211118T083000
DTEND;TZID=America/Vancouver:20211120T120000
DTSTAMP:20260408T104020
CREATED:20210920T030135Z
LAST-MODIFIED:20210920T030135Z
UID:31136-1637224200-1637409600@scienceinvancouver.com
SUMMARY:BC Cancer Summit
DESCRIPTION:Registration for the virtual 2021 BC Cancer Summit is now open! \nWe are delighted to host the BC Cancer Summit virtually this year from November 18 to 20. The Summit provides education\, professional development and relationship building opportunities for oncology professionals from all specialties and disciplines. \nThis year’s Summit will feature: \n\nKeynote presentation by the Right Honourable Beverley McLachlin\nKeynote on PRecision oncology Evidence Development in Cancer Treatment (PREDiCT) and Precision Oncology for Young People (PROFYLE)\nA selection of breakouts sessions\, a Terry Fox Research Institute (TFRI) BC Node Research Day\, and poster session\nCelebration of award recipients of the 2021 Terry Fox Medal and BC Cancer Excellence Awards\n\nClick here to register.\n\nWe look forward to having you join us at the Summit. Please register by 5 p.m.\, November 17.
URL:https://scienceinvancouver.com/event/bc-cancer-summit-2-4/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211118T083000
DTEND;TZID=America/Vancouver:20211120T120000
DTSTAMP:20260408T104020
CREATED:20210920T030135Z
LAST-MODIFIED:20210920T030135Z
UID:32596-1637224200-1637409600@scienceinvancouver.com
SUMMARY:BC Cancer Summit
DESCRIPTION:Registration for the virtual 2021 BC Cancer Summit is now open! \nWe are delighted to host the BC Cancer Summit virtually this year from November 18 to 20. The Summit provides education\, professional development and relationship building opportunities for oncology professionals from all specialties and disciplines. \nThis year’s Summit will feature: \n\nKeynote presentation by the Right Honourable Beverley McLachlin\nKeynote on PRecision oncology Evidence Development in Cancer Treatment (PREDiCT) and Precision Oncology for Young People (PROFYLE)\nA selection of breakouts sessions\, a Terry Fox Research Institute (TFRI) BC Node Research Day\, and poster session\nCelebration of award recipients of the 2021 Terry Fox Medal and BC Cancer Excellence Awards\n\nClick here to register.\n\nWe look forward to having you join us at the Summit. Please register by 5 p.m.\, November 17.
URL:https://scienceinvancouver.com/event/bc-cancer-summit-2-5/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211118T120000
DTEND;TZID=America/Vancouver:20211118T130000
DTSTAMP:20260408T104020
CREATED:20211111T005628Z
LAST-MODIFIED:20211111T005628Z
UID:19292-1637236800-1637240400@scienceinvancouver.com
SUMMARY:Investment Banking for Life Sciences - Panel Discussion
DESCRIPTION:Have you ever wondered how biotech startups get their funding or how they identify monetization strategies for their products? This panel discussion event will focus on the role of investment banks and venture capital groups in getting scientific research funded and out in the public. Our speakers will discuss how investment banks identify promising scientific advances\, evaluate strategies\, and harness the power of capital to bring ideas to life. We will hear from life sciences graduates who have successfully made a transition into the world of investment banking and are now changing the face of biotech business in Canada. \nThe Science to Business Network (www.s2bn.org) was founded 10 years ago to break down silos between universities\, industry\, government and the non-profit sector and to foster a culture of collaboration\, partnership and mutual understanding. Importantly\, the S2BN has been focused on building a network of innovative and creative individuals within and around STEM disciplines. Through panel discussions\, workshops\, mentoring programs\, a podcast and other collaborative initiatives\, the S2BN now has 9 chapters across Canada led by more than 70 grassroots volunteers whose activities now reach more than 2500 people a year. \nObjectives \nIntroduce students and early career professionals to the roles investment banks and venture capital firms play for the biotechnology industry\nIdentify key qualifications for candidates interested in transitioning into the investment banking and venture capital industry careers\nProvide information on how a scientific project is evaluated based on the investment banking criteria \nSpeaker Information \nEvelyn Pau\, PhD\nVice President\, Investment Banking and Recruiting Lead\nBloom Burton \nEvelyn Pau\, Vice President\, Investment Banking and Recruiting Lead joined Bloom Burton & Co. as an Analyst in November 2012. At Bloom Burton\, her responsibilities include monetization planning\, strategy consulting\, and scientific\, clinical and medical due diligence for pharmaceutical\, biotechnology\, and healthcare companies. Evelyn also heads Bloom Burton’s recruiting and talent management efforts as the Recruiting Lead.\nPrior to joining Bloom Burton\, Evelyn was a business development analyst at Tornado Medical Systems (now Tornado Spectral Systems) and a research fellow at SECOR Consulting (now KPMG). Evelyn completed her PhD in Immunology at the University of Toronto\, specializing in genetics and autoimmunity\, and her Bachelor of Medical Sciences Honours in Microbiology and Immunology at Western University.\nCurrently\, Evelyn serves on the Board of Directors of the McMaster Innovation Park. \nBharat Srinivasa\, PhD\nPrincipal\nAmplitude Ventures \nBharat Srinivasa is a co-founder and principal at Amplitude where he is involved in all aspects of deal flow including proving leadership in sourcing\, diligence\, and negotiation. Prior to Amplitude\, he was on the investment team at the BDC Healthcare Fund\, where he was involved in taking multiple companies public. Prior to his VC career\, Bharat was a consultant in forecasting and valuation practice at Foster Rosenblatt\, an international life science consulting firm for biotech and pharma companies where he was responsible for providing business intelligence and commercial analytics and pricing & market access analysis. Bharat has a PhD in Experimental Medicine and Masters of Science in Microbiology and Immunology from McGill University. \nSuman Rao\, PhD\nAssociate\nLumira Ventures \nSuman comes from a strong life science background\, with special expertise in oncology and developing multi-targeted strategies to treat advanced cancers. Suman joined Lumira in 2021 as an Associate and focuses on conducting scientific and technical diligence of investment opportunities. She remains extremely passionate about understanding drivers of complex diseases and through her work at Lumira Ventures\, hopes to bring novel therapies to patients by promoting cutting-edge technologies and medicines.\nPrior to joining Lumira Ventures\, Suman worked in healthcare consulting at L.E.K. Consulting in Boston as a Life Sciences Specialist. During her time at L.E.K.\, she provided strategic advice on growth opportunities\, pipeline expansion\, potential M&A partnerships and financial modeling. Before joining L.E.K.\, Suman spent 4 years doing a Postdoctoral Fellowship at Harvard Medical School and Dana Farber Cancer Institute. During this time\, she worked with a multidisciplinary team to develop therapies to treat advanced cancers. \nParas Sharma\, MSc\nAssociate\nGenesys Capital \nParas came to the Genesys team from adMare Bioinnovations\, where he was responsible for proactive identification of new opportunities\, deal sourcing\, financial valuations and company creation. Prior to his time at adMare\, he served as a Management Consultant providing primary strategic insights to big pharma\, and as a Venture Manager at the CDL.\nMr. Sharma has also held various scientific roles in early drug discovery group at Eisai Inc. and in clinical biomarker group at Alexion Pharma. He spent his early career in academic research at Abramson Cancer Center at UPenn.\nHe holds a Bachelor of Technology from Amity University\, a Master of Biotechnology from the University of Pennsylvania\, and an MBA from Sauder School of Business in University of British Columbia.
URL:https://scienceinvancouver.com/event/investment-banking-for-life-sciences-panel-discussion/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/11/Slide2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211118T120000
DTEND;TZID=America/Vancouver:20211118T130000
DTSTAMP:20260408T104020
CREATED:20211111T005628Z
LAST-MODIFIED:20211111T005628Z
UID:26466-1637236800-1637240400@scienceinvancouver.com
SUMMARY:Investment Banking for Life Sciences - Panel Discussion
DESCRIPTION:Have you ever wondered how biotech startups get their funding or how they identify monetization strategies for their products? This panel discussion event will focus on the role of investment banks and venture capital groups in getting scientific research funded and out in the public. Our speakers will discuss how investment banks identify promising scientific advances\, evaluate strategies\, and harness the power of capital to bring ideas to life. We will hear from life sciences graduates who have successfully made a transition into the world of investment banking and are now changing the face of biotech business in Canada. \nThe Science to Business Network (www.s2bn.org) was founded 10 years ago to break down silos between universities\, industry\, government and the non-profit sector and to foster a culture of collaboration\, partnership and mutual understanding. Importantly\, the S2BN has been focused on building a network of innovative and creative individuals within and around STEM disciplines. Through panel discussions\, workshops\, mentoring programs\, a podcast and other collaborative initiatives\, the S2BN now has 9 chapters across Canada led by more than 70 grassroots volunteers whose activities now reach more than 2500 people a year. \nObjectives \nIntroduce students and early career professionals to the roles investment banks and venture capital firms play for the biotechnology industry\nIdentify key qualifications for candidates interested in transitioning into the investment banking and venture capital industry careers\nProvide information on how a scientific project is evaluated based on the investment banking criteria \nSpeaker Information \nEvelyn Pau\, PhD\nVice President\, Investment Banking and Recruiting Lead\nBloom Burton \nEvelyn Pau\, Vice President\, Investment Banking and Recruiting Lead joined Bloom Burton & Co. as an Analyst in November 2012. At Bloom Burton\, her responsibilities include monetization planning\, strategy consulting\, and scientific\, clinical and medical due diligence for pharmaceutical\, biotechnology\, and healthcare companies. Evelyn also heads Bloom Burton’s recruiting and talent management efforts as the Recruiting Lead.\nPrior to joining Bloom Burton\, Evelyn was a business development analyst at Tornado Medical Systems (now Tornado Spectral Systems) and a research fellow at SECOR Consulting (now KPMG). Evelyn completed her PhD in Immunology at the University of Toronto\, specializing in genetics and autoimmunity\, and her Bachelor of Medical Sciences Honours in Microbiology and Immunology at Western University.\nCurrently\, Evelyn serves on the Board of Directors of the McMaster Innovation Park. \nBharat Srinivasa\, PhD\nPrincipal\nAmplitude Ventures \nBharat Srinivasa is a co-founder and principal at Amplitude where he is involved in all aspects of deal flow including proving leadership in sourcing\, diligence\, and negotiation. Prior to Amplitude\, he was on the investment team at the BDC Healthcare Fund\, where he was involved in taking multiple companies public. Prior to his VC career\, Bharat was a consultant in forecasting and valuation practice at Foster Rosenblatt\, an international life science consulting firm for biotech and pharma companies where he was responsible for providing business intelligence and commercial analytics and pricing & market access analysis. Bharat has a PhD in Experimental Medicine and Masters of Science in Microbiology and Immunology from McGill University. \nSuman Rao\, PhD\nAssociate\nLumira Ventures \nSuman comes from a strong life science background\, with special expertise in oncology and developing multi-targeted strategies to treat advanced cancers. Suman joined Lumira in 2021 as an Associate and focuses on conducting scientific and technical diligence of investment opportunities. She remains extremely passionate about understanding drivers of complex diseases and through her work at Lumira Ventures\, hopes to bring novel therapies to patients by promoting cutting-edge technologies and medicines.\nPrior to joining Lumira Ventures\, Suman worked in healthcare consulting at L.E.K. Consulting in Boston as a Life Sciences Specialist. During her time at L.E.K.\, she provided strategic advice on growth opportunities\, pipeline expansion\, potential M&A partnerships and financial modeling. Before joining L.E.K.\, Suman spent 4 years doing a Postdoctoral Fellowship at Harvard Medical School and Dana Farber Cancer Institute. During this time\, she worked with a multidisciplinary team to develop therapies to treat advanced cancers. \nParas Sharma\, MSc\nAssociate\nGenesys Capital \nParas came to the Genesys team from adMare Bioinnovations\, where he was responsible for proactive identification of new opportunities\, deal sourcing\, financial valuations and company creation. Prior to his time at adMare\, he served as a Management Consultant providing primary strategic insights to big pharma\, and as a Venture Manager at the CDL.\nMr. Sharma has also held various scientific roles in early drug discovery group at Eisai Inc. and in clinical biomarker group at Alexion Pharma. He spent his early career in academic research at Abramson Cancer Center at UPenn.\nHe holds a Bachelor of Technology from Amity University\, a Master of Biotechnology from the University of Pennsylvania\, and an MBA from Sauder School of Business in University of British Columbia.
URL:https://scienceinvancouver.com/event/investment-banking-for-life-sciences-panel-discussion-2/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/11/Slide2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211118T120000
DTEND;TZID=America/Vancouver:20211118T130000
DTSTAMP:20260408T104020
CREATED:20211111T005628Z
LAST-MODIFIED:20211111T005628Z
UID:28080-1637236800-1637240400@scienceinvancouver.com
SUMMARY:Investment Banking for Life Sciences - Panel Discussion
DESCRIPTION:Have you ever wondered how biotech startups get their funding or how they identify monetization strategies for their products? This panel discussion event will focus on the role of investment banks and venture capital groups in getting scientific research funded and out in the public. Our speakers will discuss how investment banks identify promising scientific advances\, evaluate strategies\, and harness the power of capital to bring ideas to life. We will hear from life sciences graduates who have successfully made a transition into the world of investment banking and are now changing the face of biotech business in Canada. \nThe Science to Business Network (www.s2bn.org) was founded 10 years ago to break down silos between universities\, industry\, government and the non-profit sector and to foster a culture of collaboration\, partnership and mutual understanding. Importantly\, the S2BN has been focused on building a network of innovative and creative individuals within and around STEM disciplines. Through panel discussions\, workshops\, mentoring programs\, a podcast and other collaborative initiatives\, the S2BN now has 9 chapters across Canada led by more than 70 grassroots volunteers whose activities now reach more than 2500 people a year. \nObjectives \nIntroduce students and early career professionals to the roles investment banks and venture capital firms play for the biotechnology industry\nIdentify key qualifications for candidates interested in transitioning into the investment banking and venture capital industry careers\nProvide information on how a scientific project is evaluated based on the investment banking criteria \nSpeaker Information \nEvelyn Pau\, PhD\nVice President\, Investment Banking and Recruiting Lead\nBloom Burton \nEvelyn Pau\, Vice President\, Investment Banking and Recruiting Lead joined Bloom Burton & Co. as an Analyst in November 2012. At Bloom Burton\, her responsibilities include monetization planning\, strategy consulting\, and scientific\, clinical and medical due diligence for pharmaceutical\, biotechnology\, and healthcare companies. Evelyn also heads Bloom Burton’s recruiting and talent management efforts as the Recruiting Lead.\nPrior to joining Bloom Burton\, Evelyn was a business development analyst at Tornado Medical Systems (now Tornado Spectral Systems) and a research fellow at SECOR Consulting (now KPMG). Evelyn completed her PhD in Immunology at the University of Toronto\, specializing in genetics and autoimmunity\, and her Bachelor of Medical Sciences Honours in Microbiology and Immunology at Western University.\nCurrently\, Evelyn serves on the Board of Directors of the McMaster Innovation Park. \nBharat Srinivasa\, PhD\nPrincipal\nAmplitude Ventures \nBharat Srinivasa is a co-founder and principal at Amplitude where he is involved in all aspects of deal flow including proving leadership in sourcing\, diligence\, and negotiation. Prior to Amplitude\, he was on the investment team at the BDC Healthcare Fund\, where he was involved in taking multiple companies public. Prior to his VC career\, Bharat was a consultant in forecasting and valuation practice at Foster Rosenblatt\, an international life science consulting firm for biotech and pharma companies where he was responsible for providing business intelligence and commercial analytics and pricing & market access analysis. Bharat has a PhD in Experimental Medicine and Masters of Science in Microbiology and Immunology from McGill University. \nSuman Rao\, PhD\nAssociate\nLumira Ventures \nSuman comes from a strong life science background\, with special expertise in oncology and developing multi-targeted strategies to treat advanced cancers. Suman joined Lumira in 2021 as an Associate and focuses on conducting scientific and technical diligence of investment opportunities. She remains extremely passionate about understanding drivers of complex diseases and through her work at Lumira Ventures\, hopes to bring novel therapies to patients by promoting cutting-edge technologies and medicines.\nPrior to joining Lumira Ventures\, Suman worked in healthcare consulting at L.E.K. Consulting in Boston as a Life Sciences Specialist. During her time at L.E.K.\, she provided strategic advice on growth opportunities\, pipeline expansion\, potential M&A partnerships and financial modeling. Before joining L.E.K.\, Suman spent 4 years doing a Postdoctoral Fellowship at Harvard Medical School and Dana Farber Cancer Institute. During this time\, she worked with a multidisciplinary team to develop therapies to treat advanced cancers. \nParas Sharma\, MSc\nAssociate\nGenesys Capital \nParas came to the Genesys team from adMare Bioinnovations\, where he was responsible for proactive identification of new opportunities\, deal sourcing\, financial valuations and company creation. Prior to his time at adMare\, he served as a Management Consultant providing primary strategic insights to big pharma\, and as a Venture Manager at the CDL.\nMr. Sharma has also held various scientific roles in early drug discovery group at Eisai Inc. and in clinical biomarker group at Alexion Pharma. He spent his early career in academic research at Abramson Cancer Center at UPenn.\nHe holds a Bachelor of Technology from Amity University\, a Master of Biotechnology from the University of Pennsylvania\, and an MBA from Sauder School of Business in University of British Columbia.
URL:https://scienceinvancouver.com/event/investment-banking-for-life-sciences-panel-discussion-3/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/11/Slide2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211118T120000
DTEND;TZID=America/Vancouver:20211118T130000
DTSTAMP:20260408T104020
CREATED:20211111T005628Z
LAST-MODIFIED:20211111T005628Z
UID:31163-1637236800-1637240400@scienceinvancouver.com
SUMMARY:Investment Banking for Life Sciences - Panel Discussion
DESCRIPTION:Have you ever wondered how biotech startups get their funding or how they identify monetization strategies for their products? This panel discussion event will focus on the role of investment banks and venture capital groups in getting scientific research funded and out in the public. Our speakers will discuss how investment banks identify promising scientific advances\, evaluate strategies\, and harness the power of capital to bring ideas to life. We will hear from life sciences graduates who have successfully made a transition into the world of investment banking and are now changing the face of biotech business in Canada. \nThe Science to Business Network (www.s2bn.org) was founded 10 years ago to break down silos between universities\, industry\, government and the non-profit sector and to foster a culture of collaboration\, partnership and mutual understanding. Importantly\, the S2BN has been focused on building a network of innovative and creative individuals within and around STEM disciplines. Through panel discussions\, workshops\, mentoring programs\, a podcast and other collaborative initiatives\, the S2BN now has 9 chapters across Canada led by more than 70 grassroots volunteers whose activities now reach more than 2500 people a year. \nObjectives \nIntroduce students and early career professionals to the roles investment banks and venture capital firms play for the biotechnology industry\nIdentify key qualifications for candidates interested in transitioning into the investment banking and venture capital industry careers\nProvide information on how a scientific project is evaluated based on the investment banking criteria \nSpeaker Information \nEvelyn Pau\, PhD\nVice President\, Investment Banking and Recruiting Lead\nBloom Burton \nEvelyn Pau\, Vice President\, Investment Banking and Recruiting Lead joined Bloom Burton & Co. as an Analyst in November 2012. At Bloom Burton\, her responsibilities include monetization planning\, strategy consulting\, and scientific\, clinical and medical due diligence for pharmaceutical\, biotechnology\, and healthcare companies. Evelyn also heads Bloom Burton’s recruiting and talent management efforts as the Recruiting Lead.\nPrior to joining Bloom Burton\, Evelyn was a business development analyst at Tornado Medical Systems (now Tornado Spectral Systems) and a research fellow at SECOR Consulting (now KPMG). Evelyn completed her PhD in Immunology at the University of Toronto\, specializing in genetics and autoimmunity\, and her Bachelor of Medical Sciences Honours in Microbiology and Immunology at Western University.\nCurrently\, Evelyn serves on the Board of Directors of the McMaster Innovation Park. \nBharat Srinivasa\, PhD\nPrincipal\nAmplitude Ventures \nBharat Srinivasa is a co-founder and principal at Amplitude where he is involved in all aspects of deal flow including proving leadership in sourcing\, diligence\, and negotiation. Prior to Amplitude\, he was on the investment team at the BDC Healthcare Fund\, where he was involved in taking multiple companies public. Prior to his VC career\, Bharat was a consultant in forecasting and valuation practice at Foster Rosenblatt\, an international life science consulting firm for biotech and pharma companies where he was responsible for providing business intelligence and commercial analytics and pricing & market access analysis. Bharat has a PhD in Experimental Medicine and Masters of Science in Microbiology and Immunology from McGill University. \nSuman Rao\, PhD\nAssociate\nLumira Ventures \nSuman comes from a strong life science background\, with special expertise in oncology and developing multi-targeted strategies to treat advanced cancers. Suman joined Lumira in 2021 as an Associate and focuses on conducting scientific and technical diligence of investment opportunities. She remains extremely passionate about understanding drivers of complex diseases and through her work at Lumira Ventures\, hopes to bring novel therapies to patients by promoting cutting-edge technologies and medicines.\nPrior to joining Lumira Ventures\, Suman worked in healthcare consulting at L.E.K. Consulting in Boston as a Life Sciences Specialist. During her time at L.E.K.\, she provided strategic advice on growth opportunities\, pipeline expansion\, potential M&A partnerships and financial modeling. Before joining L.E.K.\, Suman spent 4 years doing a Postdoctoral Fellowship at Harvard Medical School and Dana Farber Cancer Institute. During this time\, she worked with a multidisciplinary team to develop therapies to treat advanced cancers. \nParas Sharma\, MSc\nAssociate\nGenesys Capital \nParas came to the Genesys team from adMare Bioinnovations\, where he was responsible for proactive identification of new opportunities\, deal sourcing\, financial valuations and company creation. Prior to his time at adMare\, he served as a Management Consultant providing primary strategic insights to big pharma\, and as a Venture Manager at the CDL.\nMr. Sharma has also held various scientific roles in early drug discovery group at Eisai Inc. and in clinical biomarker group at Alexion Pharma. He spent his early career in academic research at Abramson Cancer Center at UPenn.\nHe holds a Bachelor of Technology from Amity University\, a Master of Biotechnology from the University of Pennsylvania\, and an MBA from Sauder School of Business in University of British Columbia.
URL:https://scienceinvancouver.com/event/investment-banking-for-life-sciences-panel-discussion-4/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/11/Slide2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211118T120000
DTEND;TZID=America/Vancouver:20211118T130000
DTSTAMP:20260408T104020
CREATED:20211111T005628Z
LAST-MODIFIED:20211111T005628Z
UID:32623-1637236800-1637240400@scienceinvancouver.com
SUMMARY:Investment Banking for Life Sciences - Panel Discussion
DESCRIPTION:Have you ever wondered how biotech startups get their funding or how they identify monetization strategies for their products? This panel discussion event will focus on the role of investment banks and venture capital groups in getting scientific research funded and out in the public. Our speakers will discuss how investment banks identify promising scientific advances\, evaluate strategies\, and harness the power of capital to bring ideas to life. We will hear from life sciences graduates who have successfully made a transition into the world of investment banking and are now changing the face of biotech business in Canada. \nThe Science to Business Network (www.s2bn.org) was founded 10 years ago to break down silos between universities\, industry\, government and the non-profit sector and to foster a culture of collaboration\, partnership and mutual understanding. Importantly\, the S2BN has been focused on building a network of innovative and creative individuals within and around STEM disciplines. Through panel discussions\, workshops\, mentoring programs\, a podcast and other collaborative initiatives\, the S2BN now has 9 chapters across Canada led by more than 70 grassroots volunteers whose activities now reach more than 2500 people a year. \nObjectives \nIntroduce students and early career professionals to the roles investment banks and venture capital firms play for the biotechnology industry\nIdentify key qualifications for candidates interested in transitioning into the investment banking and venture capital industry careers\nProvide information on how a scientific project is evaluated based on the investment banking criteria \nSpeaker Information \nEvelyn Pau\, PhD\nVice President\, Investment Banking and Recruiting Lead\nBloom Burton \nEvelyn Pau\, Vice President\, Investment Banking and Recruiting Lead joined Bloom Burton & Co. as an Analyst in November 2012. At Bloom Burton\, her responsibilities include monetization planning\, strategy consulting\, and scientific\, clinical and medical due diligence for pharmaceutical\, biotechnology\, and healthcare companies. Evelyn also heads Bloom Burton’s recruiting and talent management efforts as the Recruiting Lead.\nPrior to joining Bloom Burton\, Evelyn was a business development analyst at Tornado Medical Systems (now Tornado Spectral Systems) and a research fellow at SECOR Consulting (now KPMG). Evelyn completed her PhD in Immunology at the University of Toronto\, specializing in genetics and autoimmunity\, and her Bachelor of Medical Sciences Honours in Microbiology and Immunology at Western University.\nCurrently\, Evelyn serves on the Board of Directors of the McMaster Innovation Park. \nBharat Srinivasa\, PhD\nPrincipal\nAmplitude Ventures \nBharat Srinivasa is a co-founder and principal at Amplitude where he is involved in all aspects of deal flow including proving leadership in sourcing\, diligence\, and negotiation. Prior to Amplitude\, he was on the investment team at the BDC Healthcare Fund\, where he was involved in taking multiple companies public. Prior to his VC career\, Bharat was a consultant in forecasting and valuation practice at Foster Rosenblatt\, an international life science consulting firm for biotech and pharma companies where he was responsible for providing business intelligence and commercial analytics and pricing & market access analysis. Bharat has a PhD in Experimental Medicine and Masters of Science in Microbiology and Immunology from McGill University. \nSuman Rao\, PhD\nAssociate\nLumira Ventures \nSuman comes from a strong life science background\, with special expertise in oncology and developing multi-targeted strategies to treat advanced cancers. Suman joined Lumira in 2021 as an Associate and focuses on conducting scientific and technical diligence of investment opportunities. She remains extremely passionate about understanding drivers of complex diseases and through her work at Lumira Ventures\, hopes to bring novel therapies to patients by promoting cutting-edge technologies and medicines.\nPrior to joining Lumira Ventures\, Suman worked in healthcare consulting at L.E.K. Consulting in Boston as a Life Sciences Specialist. During her time at L.E.K.\, she provided strategic advice on growth opportunities\, pipeline expansion\, potential M&A partnerships and financial modeling. Before joining L.E.K.\, Suman spent 4 years doing a Postdoctoral Fellowship at Harvard Medical School and Dana Farber Cancer Institute. During this time\, she worked with a multidisciplinary team to develop therapies to treat advanced cancers. \nParas Sharma\, MSc\nAssociate\nGenesys Capital \nParas came to the Genesys team from adMare Bioinnovations\, where he was responsible for proactive identification of new opportunities\, deal sourcing\, financial valuations and company creation. Prior to his time at adMare\, he served as a Management Consultant providing primary strategic insights to big pharma\, and as a Venture Manager at the CDL.\nMr. Sharma has also held various scientific roles in early drug discovery group at Eisai Inc. and in clinical biomarker group at Alexion Pharma. He spent his early career in academic research at Abramson Cancer Center at UPenn.\nHe holds a Bachelor of Technology from Amity University\, a Master of Biotechnology from the University of Pennsylvania\, and an MBA from Sauder School of Business in University of British Columbia.
URL:https://scienceinvancouver.com/event/investment-banking-for-life-sciences-panel-discussion-5/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/11/Slide2.jpg
END:VEVENT
END:VCALENDAR